RU2290441C2 - Способ генетической модификации интересующего эндогенного гена или хромосомного локуса (варианты) и его использование - Google Patents
Способ генетической модификации интересующего эндогенного гена или хромосомного локуса (варианты) и его использование Download PDFInfo
- Publication number
- RU2290441C2 RU2290441C2 RU2003116125/13A RU2003116125A RU2290441C2 RU 2290441 C2 RU2290441 C2 RU 2290441C2 RU 2003116125/13 A RU2003116125/13 A RU 2003116125/13A RU 2003116125 A RU2003116125 A RU 2003116125A RU 2290441 C2 RU2290441 C2 RU 2290441C2
- Authority
- RU
- Russia
- Prior art keywords
- cells
- gene
- chromosomal locus
- endogenous gene
- genetically modified
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 191
- 238000000034 method Methods 0.000 title claims abstract description 121
- 230000002759 chromosomal effect Effects 0.000 title claims abstract description 79
- 238000012239 gene modification Methods 0.000 title claims abstract description 39
- 230000005017 genetic modification Effects 0.000 title claims abstract description 37
- 235000013617 genetically modified food Nutrition 0.000 title claims abstract description 37
- 230000008685 targeting Effects 0.000 claims abstract description 108
- 230000004048 modification Effects 0.000 claims abstract description 73
- 238000012986 modification Methods 0.000 claims abstract description 73
- 239000013598 vector Substances 0.000 claims abstract description 72
- 239000012634 fragment Substances 0.000 claims abstract description 65
- 108700028369 Alleles Proteins 0.000 claims abstract description 55
- 230000001580 bacterial effect Effects 0.000 claims abstract description 30
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 18
- 210000004027 cell Anatomy 0.000 claims description 109
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 97
- 108020004414 DNA Proteins 0.000 claims description 79
- 238000002744 homologous recombination Methods 0.000 claims description 61
- 230000006801 homologous recombination Effects 0.000 claims description 61
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 49
- 239000000523 sample Substances 0.000 claims description 41
- 210000000349 chromosome Anatomy 0.000 claims description 28
- 108091026890 Coding region Proteins 0.000 claims description 25
- 238000004445 quantitative analysis Methods 0.000 claims description 24
- 238000012217 deletion Methods 0.000 claims description 23
- 230000037430 deletion Effects 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 238000003780 insertion Methods 0.000 claims description 16
- 230000037431 insertion Effects 0.000 claims description 16
- 238000003753 real-time PCR Methods 0.000 claims description 16
- 241001529936 Murinae Species 0.000 claims description 15
- 210000002459 blastocyst Anatomy 0.000 claims description 14
- 241000283984 Rodentia Species 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 9
- 210000003754 fetus Anatomy 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 8
- 210000000287 oocyte Anatomy 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 210000004940 nucleus Anatomy 0.000 claims description 4
- 230000001588 bifunctional effect Effects 0.000 claims description 3
- 230000000052 comparative effect Effects 0.000 claims description 3
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 238000011901 isothermal amplification Methods 0.000 claims description 3
- 235000003869 genetically modified organism Nutrition 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000005215 recombination Methods 0.000 abstract 1
- 230000006798 recombination Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 32
- 238000012216 screening Methods 0.000 description 28
- 238000013459 approach Methods 0.000 description 25
- 238000005516 engineering process Methods 0.000 description 25
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 18
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 108090000333 Transgelin Proteins 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 238000010369 molecular cloning Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 210000003205 muscle Anatomy 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 206010003694 Atrophy Diseases 0.000 description 6
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 6
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 6
- 102000003932 Transgelin Human genes 0.000 description 6
- 230000037444 atrophy Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108010025815 Kanamycin Kinase Proteins 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 201000000585 muscular atrophy Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000011813 knockout mouse model Methods 0.000 description 4
- 101150066555 lacZ gene Proteins 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 210000001938 protoplast Anatomy 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000002638 denervation Effects 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000009966 trimming Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 101100356230 Escherichia coli (strain K12) recT gene Proteins 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 101150047627 pgk gene Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
- GRRNUXAQVGOGFE-KPBUCVLVSA-N (3'r,3as,4s,4'r,5'r,6r,6'r,7s,7as)-4-[(1r,2s,3r,5s,6r)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1s)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2OC3([C@@H]([C@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-KPBUCVLVSA-N 0.000 description 1
- MTIRIKBRVALRPJ-NTMALXAHSA-N (Z)-[3-aminopropyl(propan-2-yl)amino]-hydroxyimino-oxidoazanium Chemical compound CC(C)N(CCCN)[N+](\[O-])=N\O MTIRIKBRVALRPJ-NTMALXAHSA-N 0.000 description 1
- 101100355997 Bacillus subtilis (strain 168) recA gene Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101100301301 Escherichia coli (strain K12) recE gene Proteins 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100040669 F-box only protein 32 Human genes 0.000 description 1
- 101710191029 F-box only protein 32 Proteins 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013264 metal-organic assembly Substances 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 206010073131 oligoastrocytoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- -1 phospho Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 101150061231 recE gene Proteins 0.000 description 1
- 101150087770 recT gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24466500P | 2000-10-31 | 2000-10-31 | |
| US60/244,665 | 2000-10-31 | ||
| US09/732,234 US6586251B2 (en) | 2000-10-31 | 2000-12-07 | Methods of modifying eukaryotic cells |
| US09/732,234 | 2000-12-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003116125A RU2003116125A (ru) | 2005-01-20 |
| RU2290441C2 true RU2290441C2 (ru) | 2006-12-27 |
Family
ID=26936709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003116125/13A RU2290441C2 (ru) | 2000-10-31 | 2001-10-31 | Способ генетической модификации интересующего эндогенного гена или хромосомного локуса (варианты) и его использование |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6586251B2 (OSRAM) |
| EP (1) | EP1399575B1 (OSRAM) |
| JP (7) | JP5339566B2 (OSRAM) |
| KR (1) | KR100833136B1 (OSRAM) |
| CN (1) | CN100497642C (OSRAM) |
| AT (1) | ATE332388T1 (OSRAM) |
| AU (2) | AU2004802A (OSRAM) |
| BR (1) | BRPI0115096B1 (OSRAM) |
| CA (1) | CA2426398C (OSRAM) |
| CZ (1) | CZ304856B6 (OSRAM) |
| DE (1) | DE60121372T2 (OSRAM) |
| HU (1) | HU227639B1 (OSRAM) |
| MX (1) | MXPA03003797A (OSRAM) |
| NO (1) | NO332300B1 (OSRAM) |
| NZ (1) | NZ525511A (OSRAM) |
| PL (1) | PL204759B1 (OSRAM) |
| RU (1) | RU2290441C2 (OSRAM) |
| WO (1) | WO2002036789A2 (OSRAM) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2514672C2 (ru) * | 2008-06-27 | 2014-04-27 | Эвоник Рем ГмбХ | Рекомбинантная клетка, продуцирующая 2-гидроксиизомасляную кислоту |
| RU2656159C2 (ru) * | 2012-09-07 | 2018-05-31 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Локусы функциональности fad2 и соответствующие специфичные к участку-мишени связывающие белки, способные индуцировать направленные разрывы |
| RU2676708C2 (ru) * | 2013-04-16 | 2019-01-10 | Регенерон Фармасьютикалс, Инк. | Направленная модификация генома крысы |
| RU2685914C1 (ru) * | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| RU2734770C2 (ru) * | 2014-11-21 | 2020-10-23 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк |
| RU2749717C2 (ru) * | 2015-11-24 | 2021-06-16 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способ временной трансфекции для продуцирования ретровируса |
| RU2751237C1 (ru) * | 2020-06-10 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| RU2752498C2 (ru) * | 2015-11-24 | 2021-07-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Стабильные клеточные линии для продуцирования ретровирусов |
Families Citing this family (207)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6908744B1 (en) * | 2000-03-14 | 2005-06-21 | Regeneron Pharmaceuticals, Inc. | Methods of stimulating cartilage formation |
| DK1311661T3 (da) * | 2000-08-14 | 2012-11-26 | Us Gov Health & Human Serv | Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner |
| US6586251B2 (en) * | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| EP2361966A1 (en) | 2002-05-17 | 2011-08-31 | Mount Sinai School of Medicine of New York University | Mesoderm and definitive endoderm cell populations |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| JP2005537805A (ja) * | 2002-09-09 | 2005-12-15 | カリフォルニア インスティチュート オブ テクノロジー | ヒト化マウスを作成するための方法および組成物 |
| WO2004067725A2 (en) * | 2003-01-30 | 2004-08-12 | Regeneron Pharmaceuticals, Inc. | Methods of identifying modulators of nmur2-mediated activity |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP2395017A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| PT2767161T (pt) | 2004-10-19 | 2018-04-20 | Regeneron Pharma | Método para gerar um animal homozigótico para uma modificação genética |
| US20060117396A1 (en) * | 2004-11-30 | 2006-06-01 | Murphy Andrew J | Assay methods for identifying modulators of OPSDL3 and transgenic knockouts |
| HUE041818T2 (hu) | 2007-03-22 | 2019-05-28 | Biogen Ma Inc | Kötõ proteinek, beleértve az antitesteket, CD154-et specifikusan kötõ antitest származékokat és antitest fragmenseket is, és alkalmazásaik |
| PT2336329E (pt) | 2007-06-01 | 2012-12-24 | Omt Inc | Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos |
| US20110119779A1 (en) * | 2007-12-10 | 2011-05-19 | Aliva Biopharmaceuticals, Inc. | Methods for sequential replacement of targeted region by homologous recombination |
| AU2009238629C1 (en) * | 2008-04-14 | 2015-04-30 | Sangamo Therapeutics, Inc. | Linear donor constructs for targeted integration |
| US20090328240A1 (en) * | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| KR101987351B1 (ko) | 2008-09-30 | 2019-06-10 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 인간 이외의 포유동물 |
| PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| ES2700852T3 (es) | 2009-10-06 | 2019-02-19 | Regeneron Pharma | Ratones modificados genéticamente e injerto |
| AU2010319894B2 (en) | 2009-10-29 | 2015-03-05 | Regeneron Pharmaceuticals, Inc. | Multifunctional alleles |
| CN104131035A (zh) | 2009-12-10 | 2014-11-05 | 瑞泽恩制药公司 | 生产重链抗体的小鼠 |
| SG181690A1 (en) | 2009-12-21 | 2012-07-30 | Regeneron Pharma | Humanized fcy r mice |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| DK2505654T4 (da) | 2010-02-08 | 2020-07-27 | Regeneron Pharma | Mus med fælles letkæde |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| PL2553100T3 (pl) | 2010-03-31 | 2018-03-30 | Ablexis, Llc | Inżynieria genetyczna zwierząt nie będących ludźmi w celu wytworzenia przeciwciał chimerycznych |
| WO2011159847A2 (en) | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| RU2601297C2 (ru) | 2010-06-22 | 2016-10-27 | Ридженерон Фармасьютикалз, Инк. | Мыши, экспрессирующие гибридную легкую цепь иммуноглобулина |
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| AU2011286185B2 (en) | 2010-07-26 | 2014-08-14 | Trianni, Inc. | Transgenic animals and methods of use |
| CA3250882A1 (en) | 2010-08-02 | 2025-11-29 | Regeneron Pharamaceuticals, Inc. | Mice that Make Binding Proteins Comprising VL Domains |
| WO2012063048A1 (en) | 2010-11-08 | 2012-05-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
| WO2012097313A2 (en) | 2011-01-14 | 2012-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| DK3375284T3 (da) | 2011-02-15 | 2023-06-12 | Univ Yale | Humaniserede M-CSF-mus og anvendelser deraf |
| US10920242B2 (en) | 2011-02-25 | 2021-02-16 | Recombinetics, Inc. | Non-meiotic allele introgression |
| SI2738258T2 (sl) | 2011-02-25 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Miši ADAM6 |
| DK2527842T3 (da) | 2011-05-12 | 2013-09-08 | Regeneron Pharma | Neuropeptidfrisætningsanalyse til natriumkanaler |
| MY172718A (en) * | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
| EP3741862A1 (en) | 2011-09-19 | 2020-11-25 | Kymab Limited | Animals, repertoires & methods for the production of human antibodies |
| WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| MY172946A (en) | 2011-10-17 | 2019-12-16 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
| SMT202200205T1 (it) | 2011-10-28 | 2022-07-21 | Regeneron Pharma | Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii |
| AU2012324016C1 (en) | 2011-10-28 | 2018-02-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| ES2858978T3 (es) | 2011-10-28 | 2021-09-30 | Regeneron Pharma | Ratones con receptores de linfocitos T genéticamente modificados |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| JP2014532655A (ja) | 2011-10-31 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ナノ懸濁過程 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| KR102081657B1 (ko) | 2011-12-20 | 2020-02-26 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
| EP3597038B1 (en) | 2012-02-01 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Humanized rodents that express heavy chains containing vl domains |
| JP2015509380A (ja) | 2012-03-06 | 2015-03-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 共通の軽鎖のマウス |
| NZ730271A (en) | 2012-03-16 | 2022-09-30 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| CN104302170B (zh) | 2012-03-16 | 2016-09-28 | 瑞泽恩制药公司 | 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠 |
| ES2665793T3 (es) | 2012-03-16 | 2018-04-27 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| EP2831245A1 (en) | 2012-03-28 | 2015-02-04 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| KR101904508B1 (ko) | 2012-04-25 | 2018-10-04 | 리제너론 파마슈티칼스 인코포레이티드 | 큰 표적화 벡터를 사용한 뉴클레아제-중재된 표적화 |
| HUE055617T2 (hu) | 2012-06-12 | 2021-12-28 | Regeneron Pharma | Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények |
| AR091482A1 (es) * | 2012-06-21 | 2015-02-04 | Recombinetics Inc | Celulas modificadas geneticamente y metodos par su obtencion |
| AR092219A1 (es) | 2012-08-23 | 2015-04-08 | Seattle Genetics Inc | Conjugados anticuerpo-farmaco (adc) que se unen a proteinas 158p1d7 |
| KR101935088B1 (ko) | 2012-08-24 | 2019-01-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
| EP4193834B1 (en) | 2012-09-07 | 2025-05-14 | Yale University | Methods of using genetically modified mice |
| KR102402806B1 (ko) | 2012-11-05 | 2022-05-30 | 리제너론 파마슈티칼스 인코포레이티드 | 유전자 변형된 비-인간 동물 및 그것의 사용 방법 |
| CA2900832A1 (en) | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized t-cell co-receptors |
| EP2958990B1 (en) | 2013-02-20 | 2019-10-16 | Regeneron Pharmaceuticals, Inc. | Genetic modification of rats |
| ES2678221T3 (es) * | 2013-02-20 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas |
| WO2014130667A1 (en) | 2013-02-22 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| AU2014249150B2 (en) | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules |
| CA2903025C (en) | 2013-03-11 | 2025-10-07 | Regeneron Pharmaceuticals, Inc. | TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULES |
| EP2970437A1 (en) | 2013-03-13 | 2016-01-20 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| LT3501272T (lt) | 2013-03-13 | 2023-03-27 | Regeneron Pharmaceuticals, Inc. | Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| JP6510518B2 (ja) | 2013-08-01 | 2019-05-08 | アジェンシス，インコーポレイテッド | Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ） |
| SG11201600036QA (en) | 2013-08-07 | 2016-02-26 | Regeneron Pharma | Lincrna-deficient non-human animals |
| SG10201810825YA (en) | 2013-09-18 | 2019-01-30 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| LT3175706T (lt) | 2013-09-23 | 2019-02-25 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, turintys humanizuotą signalą reguliuojančio baltymo geną |
| NL2013554B1 (en) | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
| US20150143559A1 (en) | 2013-11-19 | 2015-05-21 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| WO2015077071A1 (en) | 2013-11-19 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| ES2700596T3 (es) | 2013-12-11 | 2019-02-18 | Regeneron Pharma | Métodos y composiciones para la modificación dirigida de un genoma |
| JP6593595B2 (ja) | 2014-01-15 | 2019-10-23 | 正道 山本 | Ａｔｐ可視化動物およびその用途 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| BR112016021679A2 (pt) | 2014-03-21 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| RU2711744C1 (ru) | 2014-05-19 | 2020-01-21 | Ридженерон Фармасьютикалз, Инк. | Генетически модифицированные животные, отличные от человека, экспрессирующие epo человека |
| EP3381279B1 (en) | 2014-05-30 | 2021-04-14 | Regeneron Pharmaceuticals, Inc. | Humanized dipeptidyl peptidase iv (dpp4) animals |
| JP6688231B2 (ja) | 2014-06-06 | 2020-04-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的遺伝子座を修飾するための方法及び組成物 |
| RS60097B1 (sr) | 2014-06-19 | 2020-05-29 | Regeneron Pharma | Ne-humane životinje koje imaju humanizovani gen za programiranu ćelijsku smrt 1 |
| DK3354732T3 (da) | 2014-06-23 | 2020-04-06 | Regeneron Pharma | Nukleasemedieret dna-samling |
| EP3161128B1 (en) | 2014-06-26 | 2018-09-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| RU2017113134A (ru) | 2014-09-19 | 2018-10-19 | Регенерон Фармасьютикалз, Инк. | Химерные антигенные рецепторы |
| KR20170070136A (ko) | 2014-10-15 | 2017-06-21 | 리제너론 파마슈티칼스 인코포레이티드 | 만능성 세포를 생성하거나 유지하는 방법 및 조성물 |
| CA2967823A1 (en) | 2014-11-24 | 2016-06-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing humanized cd3 complex |
| SMT201900178T1 (it) | 2014-12-05 | 2019-05-10 | Regeneron Pharma | Animali diversi dall’uomo aventi un gruppo umanizzato del gene 47 di differenziazione |
| IL282649B (en) | 2014-12-09 | 2022-07-01 | Regeneron Pharma | Non-human animals with a humanized gene for differentiation cluster 274 |
| EP3653048B9 (en) | 2014-12-19 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification through single-step multiple targeting |
| CN107614010A (zh) | 2015-03-09 | 2018-01-19 | 艾更斯司股份有限公司 | 结合至flt3蛋白的抗体药物偶联物(adc) |
| ES2955841T3 (es) | 2015-03-16 | 2023-12-07 | Regeneron Pharma | Célula de un roedor que presenta función de la neurona motora superior e inferior y percepción sensorial disminuidas |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| RS64540B1 (sr) | 2015-04-06 | 2023-09-29 | Regeneron Pharma | Imunski odgovori posredovani humanizovanim t ćelijama kod ne-humanih životinja |
| WO2016168212A1 (en) | 2015-04-13 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Humanized sirpa-il15 knockin mice and methods of use thereof |
| US10395759B2 (en) | 2015-05-18 | 2019-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for copy number variant detection |
| EP3297663B1 (en) | 2015-05-18 | 2025-11-12 | Agensys, Inc. | Antibodies that bind to axl proteins |
| WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| US10285388B2 (en) * | 2015-05-29 | 2019-05-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a C9ORF72 locus |
| US10412939B2 (en) | 2015-09-02 | 2019-09-17 | Regeneron Pharmaceuticals, Inc. | Rodent model of prostate cancer |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| PL3376857T3 (pl) * | 2015-11-20 | 2021-09-13 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż człowiek posiadające humanizowany gen aktywacji limfocytów 3 |
| WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| SG10201914034WA (en) | 2016-01-13 | 2020-03-30 | Regeneron Pharma | Rodents having an engineered heavy chain diversity region |
| US20170218398A1 (en) * | 2016-01-30 | 2017-08-03 | Markus Alexander Brown | Method to selectively target cancerous cells for genetic manipulation |
| CN108779159B (zh) * | 2016-02-04 | 2022-12-30 | 瑞泽恩制药公司 | 具有经改造的angptl8基因的非人动物 |
| US11053288B2 (en) | 2016-02-04 | 2021-07-06 | Trianni, Inc. | Enhanced production of immunoglobulins |
| US12071669B2 (en) | 2016-02-12 | 2024-08-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for detection of abnormal karyotypes |
| US20170247436A1 (en) | 2016-02-16 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a mutant kynureninase gene |
| EP3422845B1 (en) | 2016-02-29 | 2021-06-02 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| WO2017172958A1 (en) | 2016-03-29 | 2017-10-05 | Regeneron Pharmaceuticals, Inc. | Genetic variant-phenotype analysis system and methods of use |
| JP7324583B2 (ja) | 2016-05-20 | 2023-08-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法 |
| PT3462853T (pt) | 2016-06-03 | 2023-04-21 | Regeneron Pharma | Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| DK3476865T5 (da) | 2016-06-28 | 2024-09-09 | Biocytogen Pharmaceuticals Beijing Co Ltd | Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf |
| CN109803530A (zh) | 2016-07-29 | 2019-05-24 | 瑞泽恩制药公司 | 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠 |
| EP3518667B1 (en) * | 2016-09-30 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Rodents having a hexanucleotide repeat expansion in a c9orf72 locus |
| DK3766343T3 (da) | 2016-11-04 | 2022-06-20 | Regeneron Pharma | Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus |
| JP2020505037A (ja) | 2017-01-19 | 2020-02-20 | オープン モノクローナル テクノロジー，インコーポレイテッド | 複数の重鎖免疫グロブリン遺伝子座を有するトランスジェニックげっ歯類由来のヒト抗体 |
| WO2018157058A1 (en) | 2017-02-27 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of retinoschisis |
| CA3067872A1 (en) | 2017-07-31 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
| EP3585160A2 (en) | 2017-07-31 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Crispr reporter non-human animals and uses thereof |
| DK3687287T5 (da) | 2017-09-29 | 2024-08-26 | Regeneron Pharma | Gnavere, udtrykkende humaniseret c1q-kompleks |
| BR112020003609A2 (pt) | 2017-09-29 | 2020-09-01 | Regeneron Pharmaceuticals, Inc. | sistema e método para formar uma emulsão |
| WO2019072241A1 (en) * | 2017-10-13 | 2019-04-18 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC |
| CN109666701B (zh) * | 2017-10-13 | 2021-08-24 | 百奥赛图(北京)医药科技股份有限公司 | 一种pd-1基因修饰人源化动物模型的构建方法及其应用 |
| CN116064611A (zh) | 2017-11-30 | 2023-05-05 | 瑞泽恩制药公司 | 包含人源化trkb基因座的非人动物 |
| CN116058333A (zh) | 2017-12-05 | 2023-05-05 | 瑞泽恩制药公司 | 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途 |
| EP3592140A1 (en) | 2018-03-19 | 2020-01-15 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
| CN116420679B (zh) | 2018-03-26 | 2025-10-03 | 瑞泽恩制药公司 | 用于测试治疗剂的人源化啮齿动物 |
| HRP20250986T1 (hr) | 2018-04-06 | 2025-10-24 | Regeneron Pharmaceuticals, Inc. | Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije |
| CN112639980A (zh) | 2018-06-01 | 2021-04-09 | 瑞泽恩制药公司 | 用于基于稀疏向量的矩阵变换的方法和系统 |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| WO2020018511A1 (en) | 2018-07-16 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animal models of ditra disease and uses thereof |
| CN109504708A (zh) * | 2018-12-03 | 2019-03-22 | 江苏集萃药康生物科技有限公司 | 一种筛选标记自我删除的基因打靶载体及方法 |
| IL301193A (en) | 2018-12-20 | 2023-05-01 | Regeneron Pharma | Nuclease-mediated repeat expansion |
| US20220104468A1 (en) | 2019-01-22 | 2022-04-07 | St. Jude Children's Research Hospital | Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration |
| KR20210133234A (ko) * | 2019-02-18 | 2021-11-05 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 인간화 면역글로불린 유전자좌를 갖는 유전적으로 변형된 비-인간 동물 |
| CA3127153A1 (en) | 2019-02-22 | 2020-08-27 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
| KR102487901B1 (ko) | 2019-04-04 | 2023-01-12 | 리제너론 파마슈티칼스 인코포레이티드 | 표적화된 변형의 표적화 벡터로의 무흔적 도입을 위한 방법 |
| AU2020253532B2 (en) | 2019-04-04 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| JP2022529943A (ja) | 2019-04-15 | 2022-06-27 | クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー | がんの処置における使用のための、標的指向性のマスクされたｉ型インターフェロン（ｉｆｎａおよびｉｆｎｂ）と腫瘍抗原に対する抗体とを含む融合タンパク質組成物 |
| CN113874510A (zh) | 2019-06-04 | 2021-12-31 | 瑞泽恩制药公司 | 包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法 |
| KR20220016880A (ko) | 2019-06-05 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 카파 유전자좌에서 발현된 제한적 람다 경쇄 레퍼토리를 갖는 비-인간 동물 및 이의 용도 |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| KR20220024134A (ko) | 2019-06-27 | 2022-03-03 | 리제너론 파마슈티칼스 인코포레이티드 | Tdp-43 단백질이상질환 모델링 |
| CA3145453A1 (en) | 2019-07-01 | 2021-01-07 | Tonix Pharma Limited | Anti-cd154 antibodies and uses thereof |
| MX2022003935A (es) | 2019-10-04 | 2022-04-25 | Tae Life Sciences Llc | Composiciones de anticuerpo que comprenden mutaciones fc y propiedades de conjugacion especificas del sitio. |
| WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
| EP4096396A1 (en) | 2020-01-28 | 2022-12-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized pnpla3 locus and methods of use |
| US20230081547A1 (en) | 2020-02-07 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized klkb1 locus and methods of use |
| EP4125348A1 (en) | 2020-03-23 | 2023-02-08 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
| KR20230004472A (ko) | 2020-04-21 | 2023-01-06 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 cxcl13 유전자를 갖는 비인간 동물 |
| AU2021283564B2 (en) | 2020-06-02 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
| AU2020454777A1 (en) | 2020-06-25 | 2023-02-02 | Humab Co., Ltd. | Heterozygous transgenic animal |
| IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
| WO2022072671A1 (en) | 2020-10-01 | 2022-04-07 | Regeneron Pharmaceuticals, Inc. | Rodent animals expressing human cr1 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CN116802200A (zh) | 2020-12-21 | 2023-09-22 | 瑞泽恩制药公司 | 具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物 |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| JP2024503625A (ja) | 2021-01-06 | 2024-01-26 | トニックス ファーマ リミテッド | 改変された抗ｃｄ１５４抗体により免疫寛容を誘導する方法 |
| JP2024512702A (ja) | 2021-03-31 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス |
| WO2022220603A1 (ko) | 2021-04-16 | 2022-10-20 | 고려대학교 산학협력단 | 코로나-19 바이러스 표적 인간 항체 |
| US20250325634A1 (en) | 2021-06-18 | 2025-10-23 | Nammi Therapeutics, Inc. | Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNa and IFNb) For Use in the Treatment of Cancer and Methods Thereof |
| US20240415980A1 (en) | 2021-10-28 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-related methods and compositions for knocking out c5 |
| IL312971A (en) | 2021-12-08 | 2024-07-01 | Regeneron Pharma | Mutant myocilin disease model and uses thereof |
| EP4451863A1 (en) | 2021-12-20 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising humanized ace2 and tmprss loci |
| WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
| EP4476245A1 (en) | 2022-02-11 | 2024-12-18 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
| EP4514125A1 (en) | 2022-04-26 | 2025-03-05 | Regeneron Pharmaceuticals, Inc. | A rodent model of fibrodysplasia ossificans progressiva |
| WO2023235677A1 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Animal model of tdp-43 proteinopathy |
| WO2023235725A2 (en) | 2022-05-31 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Crispr-based therapeutics for c9orf72 repeat expansion disease |
| US20230417899A1 (en) | 2022-06-27 | 2023-12-28 | Oshkosh Corporation | Position tracking for a lift device |
| CN119654068A (zh) | 2022-07-19 | 2025-03-18 | 瑞泽恩制药公司 | 转基因动物模型及其模拟人类免疫系统的用途 |
| CA3265746A1 (en) | 2022-09-22 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM |
| US20240224964A9 (en) | 2022-09-29 | 2024-07-11 | Regeneron Pharmaceuticals, Inc. | Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes |
| AU2024214456A1 (en) | 2023-02-01 | 2025-07-03 | Regeneron Pharmaceuticals, Inc. | Animals comprising a modified klhdc7b locus |
| WO2024258743A1 (en) | 2023-06-13 | 2024-12-19 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| AU2024304358A1 (en) | 2023-06-16 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025122669A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized complement factor b gene |
| WO2025171307A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
| WO2025235388A1 (en) | 2024-05-06 | 2025-11-13 | Regeneron Pharmaceuticals, Inc. | Transgene genomic identification by nuclease-mediated long read sequencing |
| WO2025250495A1 (en) | 2024-05-28 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| SG48760A1 (en) * | 1992-07-24 | 2003-03-18 | Abgenix Inc | Generation of xenogenetic antibodies |
| DE4228162C1 (de) * | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
| US5436149A (en) | 1993-02-19 | 1995-07-25 | Barnes; Wayne M. | Thermostable DNA polymerase with enhanced thermostability and enhanced length and efficiency of primer extension |
| AU6819494A (en) * | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO2000046251A2 (en) * | 1999-02-05 | 2000-08-10 | Buelow Jens Ulrich | Human polyclonal antibodies from transgenic nonhuman animals |
| US6586251B2 (en) * | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
-
2000
- 2000-12-07 US US09/732,234 patent/US6586251B2/en not_active Expired - Lifetime
-
2001
- 2001-10-31 BR BRPI0115096A patent/BRPI0115096B1/pt active IP Right Grant
- 2001-10-31 WO PCT/US2001/045375 patent/WO2002036789A2/en not_active Ceased
- 2001-10-31 CA CA2426398A patent/CA2426398C/en not_active Expired - Lifetime
- 2001-10-31 HU HU0301575A patent/HU227639B1/hu unknown
- 2001-10-31 DE DE60121372T patent/DE60121372T2/de not_active Expired - Lifetime
- 2001-10-31 JP JP2002539535A patent/JP5339566B2/ja not_active Expired - Lifetime
- 2001-10-31 AT AT01992495T patent/ATE332388T1/de not_active IP Right Cessation
- 2001-10-31 NZ NZ525511A patent/NZ525511A/en not_active IP Right Cessation
- 2001-10-31 AU AU2004802A patent/AU2004802A/xx active Pending
- 2001-10-31 EP EP01992495A patent/EP1399575B1/en not_active Expired - Lifetime
- 2001-10-31 KR KR1020037005885A patent/KR100833136B1/ko not_active Expired - Lifetime
- 2001-10-31 PL PL361927A patent/PL204759B1/pl unknown
- 2001-10-31 CN CNB018216609A patent/CN100497642C/zh not_active Expired - Lifetime
- 2001-10-31 RU RU2003116125/13A patent/RU2290441C2/ru active
- 2001-10-31 MX MXPA03003797A patent/MXPA03003797A/es active IP Right Grant
- 2001-10-31 AU AU2002220048A patent/AU2002220048B2/en not_active Expired
- 2001-10-31 CZ CZ2003-1197A patent/CZ304856B6/cs not_active IP Right Cessation
-
2003
- 2003-04-28 NO NO20031897A patent/NO332300B1/no not_active IP Right Cessation
-
2010
- 2010-06-15 JP JP2010136321A patent/JP2010220628A/ja active Pending
-
2013
- 2013-05-23 JP JP2013108631A patent/JP5892975B2/ja not_active Expired - Lifetime
- 2013-11-29 JP JP2013247817A patent/JP5945263B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-26 JP JP2014265082A patent/JP2015062432A/ja not_active Withdrawn
-
2017
- 2017-02-14 JP JP2017024802A patent/JP2017123855A/ja not_active Withdrawn
- 2017-02-14 JP JP2017024803A patent/JP6486979B2/ja not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| YANG X.W. et al., "Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome", Nat Biotechnol. 1997 Sep; 15(9):859-65. * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2514672C2 (ru) * | 2008-06-27 | 2014-04-27 | Эвоник Рем ГмбХ | Рекомбинантная клетка, продуцирующая 2-гидроксиизомасляную кислоту |
| RU2514672C9 (ru) * | 2008-06-27 | 2014-10-20 | Эвоник Рем ГмбХ | Рекомбинантная клетка, продуцирующая 2-гидроксиизомасляную кислоту |
| RU2656159C2 (ru) * | 2012-09-07 | 2018-05-31 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Локусы функциональности fad2 и соответствующие специфичные к участку-мишени связывающие белки, способные индуцировать направленные разрывы |
| RU2656158C2 (ru) * | 2012-09-07 | 2018-05-31 | ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи | Функциональные локусы fad2 и соответствующие специфичные для сайта-мишени связывающиеся белки, способные индуцировать направленные разрывы |
| RU2676708C2 (ru) * | 2013-04-16 | 2019-01-10 | Регенерон Фармасьютикалс, Инк. | Направленная модификация генома крысы |
| RU2685914C1 (ru) * | 2013-12-11 | 2019-04-23 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| RU2725520C2 (ru) * | 2013-12-11 | 2020-07-02 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| RU2734770C2 (ru) * | 2014-11-21 | 2020-10-23 | Регенерон Фармасьютикалз, Инк. | Способы и композиции для нацеленной генетической модификации с использованием парных гидовых рнк |
| RU2749717C2 (ru) * | 2015-11-24 | 2021-06-16 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способ временной трансфекции для продуцирования ретровируса |
| RU2752498C2 (ru) * | 2015-11-24 | 2021-07-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Стабильные клеточные линии для продуцирования ретровирусов |
| RU2751237C1 (ru) * | 2020-06-10 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2290441C2 (ru) | Способ генетической модификации интересующего эндогенного гена или хромосомного локуса (варианты) и его использование | |
| US10344299B2 (en) | Compositions and methods for modifying cells | |
| AU2002220048A1 (en) | Methods of modifying eukaryotic cells | |
| US8791323B2 (en) | Hybrid antibodies comprising human variable regions and mouse constant regions produced in a genetically modified mouse | |
| IL155580A (en) | Ex vivo method for modifying endogenous gene or chromosomal locus in eukaryotic cells | |
| HK1059802B (en) | Methods of modifying eukaryotic cells |